Fred Aslan's Planned Sale of Artiva Biotherapeutics Common Stock

Fred Aslan, a director and officer of Artiva Biotherapeutics, Inc., has filed a Form 144 to notify the SEC of his intention to sell 25,500 shares of the company's common stock. The shares were acquired on August 15, 2025, as Restricted Stock Units. The sale is planned to occur on or around October 17, 2025, with an aggregate market value of $70,635.00. The sale will be executed through Morgan Stanley Smith Barney LLC Executive Financial Services. Aslan has also reported a recent sale of 25,500 shares on August 15, 2025, which generated gross proceeds of $69,579.30. The filing indicates that Aslan is following a pre-arranged trading plan adopted on July 23, 2024.